Weighing the benefits of high-dose simvastatin ... [N Engl J Med. 2011] - PubMed

loading

[The last round about statins: there is the fact that 80 mg simvastatin daily results in high risk of myopathy]. [Lakartidningen. 2009]
[The last round about statins: there is the fact that 80 mg simvastatin daily results in high risk of myopathy].
Olsson AG. Lakartidningen. 2009 Oct 21-27; 106(43):2783-4; author reply 2784.
Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. [J Manag Care Pharm. 2010]
Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
Karimi S, Hough A, Beckey C, Parra D. J Manag Care Pharm. 2010 Sep; 16(7):472-81.
[Warning for simvastatin 80 mg!]. [Lakartidningen. 2009]
[Warning for simvastatin 80 mg!].
Olsson AG. Lakartidningen. 2009 Sep 30-Oct 6; 106(40):2549-50.
Review New simvastatin dosing recommendations. [Med Lett Drugs Ther. 2011]
Review New simvastatin dosing recommendations.
[No authors listed]Med Lett Drugs Ther. 2011 Aug 25; 53(1370):61-2.
Review Does simvastatin cause more myotoxicity compared with other statins? [Ann Pharmacother. 2009]
Review Does simvastatin cause more myotoxicity compared with other statins?
Backes JM, Howard PA, Ruisinger JF, Moriarty PM. Ann Pharmacother. 2009 Dec; 43(12):2012-20. Epub 2009 Nov 17.

A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. [PLoS One. 2012]
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB, Kraus C, Dimbil M, Golomb BA. PLoS One. 2012; 7(8):e42866. Epub 2012 Aug 22.
Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. [JAMA. 2012]
Use of administrative data to estimate the incidence of statin-related rhabdomyolysis.
Floyd JS, Heckbert SR, Weiss NS, Carrell DS, Psaty BM. JAMA. 2012 Apr 18; 307(15):1580-2.
Review Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. [Pharmacogenomics. 2012]
Review Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.
Feng Q, Wilke RA, Baye TM. Pharmacogenomics. 2012 Apr; 13(5):579-94.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Weighing the benefits of high-dose simvastatin against the risk of myopathy.
Weighing the benefits of high-dose simvastatin against the risk of myopathy.
N Engl J Med. 2011 Jul 28 ;365(4):285-7. doi: 10.1056/NEJMp1106689. Epub 2011 Jun 15 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed